Third party funding
- DFG SFB 576
- DFG SFB_TR36
- Helmholtz Alliance “Immunotherapy of Cancer”, Focus Hepatocellular Carcionoma
- BMBF Consortium HOPE („Hepatitis B Therapy Optimized by Phenotypic Evaluation“): Coordinator and Principal Investigator
- EU, AVIP consortium
Research collaborations:
- Roche Inc., Paolo Alto, CA, USA
- Siemens Molecular Diagnostics, Berkley, USA
- Micromet Inc., Munich, Germany
- Rheinbiotech – Dynavax Europe, Düsseldorf, Germany